Earnings History Data for Ensysce Biosciences (ENSC) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Ensysce Biosciences

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
15-03-2024	PM	ENSC	Ensysce Biosciences	2.00	-1.13	-0.86	0.00	Ensysce Biosciences reports Q4 results [3/15/2024 10:26 AM]	0.7915	0.04 (5.53%)	0.74	-0.01 (-1.83%)	0.72 - 8.90	223,160	250,000	3,825
Ensysce Biosciences reports Q4 results [3/15/2024 10:26 AM]
09-11-2023	AH	ENSC	Ensysce Biosciences	3.00	-0.87	-1.06	0.00	Ensysce Biosciences reports Q3 results [11/10/2023 10:17 AM]	0.8142	-0.04 (-4.22%)	0.85	0.0 (0.47%)	0.81 - 56.52	43,187	50,000	3,465
Ensysce Biosciences files to sell 6.18M shares of common stocks for holders [11/9/2023 6:04 PM] Ensysce Biosciences reports Q3 results [11/10/2023 10:17 AM]
15-05-2023	PM	ENSC	Ensysce Biosciences	4.00	-2.08	-13.91	0.00	Ensysce Biosciences GAAP EPS of -$2.08 beats by $8.81 [5/16/2023 3:49 AM]	2.96	-0.12 (-3.73%)	3.00	-0.08 (-2.60%)	2.82 - 220.80	78,950	3,180,000	4,511
Ensysce Biosciences GAAP EPS of -$2.08 beats by $8.81 [5/16/2023 3:49 AM]
30-03-2023	PM	ENSC	Ensysce Biosciences, Inc.	8.07	-1.52	-2.59	9.00	Ensysce Biosciences GAAP EPS of -$1.52 beats by $0.89, revenue of $1.43M misses by $0.11M [3/31/2023 12:35 AM]	4.86	-1.93 (-28.43%)	6.25	-0.54 (-7.96%)	4.68 - 396.00	175,113	90,000	9,778
Ensysce Biosciences GAAP EPS of -$1.52 beats by $0.89, revenue of $1.43M misses by $0.11M [3/31/2023 12:35 AM]
14-11-2022	PM	ENSC	Ensysce Biosciences	4.00	-5.13	-3.00	0.00	Ensysce Biosciences GAAP EPS of -$5.13 [11/15/2022 9:09 AM]	2.15	-0.22 (-9.28%)	2.35	-0.02 (-0.84%)	1.90 - 140.00	626,436	1,100,000	35,881
Ensysce Biosciences rises 12% as co to develop lead candidate PF614 for acute pain treatment [11/14/2022 9:05 AM] Ensysce Biosciences GAAP EPS of -$5.13 [11/15/2022 9:09 AM] Ensysce Biosciences Reports Third Quarter 2022 Financial Results [Nov-14-22 04:30PM] Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 [Nov-14-22 08:05AM]
11-08-2022	AH	ENSC	Ensysce Biosciences	19.00	-0.24	-0.21	0.00	Ensysce Biosciences GAAP EPS of -$0.24, revenue of $0.2M [8/11/2022 5:34 PM]	0.4807	-0.02 (-4.36%)	0.50	0.0 (-0.52%)	0.39 - 7.00	522,149	540,000	3,137
Ensysce Biosciences GAAP EPS of -$0.24, revenue of $0.2M [8/11/2022 5:34 PM] Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results [Aug-11-22 04:10PM]
31-03-2022	AH	ENSC	Ensysce Biosciences, Inc.	26.20	-0.45	0.09	0.00	Ensysce Biosciences reports Q4 results [3/31/2022 5:16 PM]	1.10	-0.04 (-3.51%)	1.06	-0.08 (-7.02%)	0.87 - 17.12	346,709	450,000	53,411
Ensysce Biosciences reports Q4 results [3/31/2022 5:16 PM] Ensysce Biosciences Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results [Mar-31-22 04:05PM]